Clinical trials
Lung Cancer Patients clinical trials
Below are recruiting lung cancer patients clinical trials, each written for real people, not researchers. We’re tracking 1,877 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07649928RecruitingEarly Phase 1
Testing ES502 for Advanced Pancreatic and Other Cancers
This early-stage trial tests a new drug called ES502 for patients with advanced cancers (including pancreatic cancer) that have a specific genetic mutation and certain immune markers. The study aims to find the right dose and see if it helps shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06718738RecruitingPhase 1
IM96 CAR-T for advanced colorectal cancer
This trial tests a new cell therapy called IM96 CAR-T, which targets a protein (GUCY2C) found on tumor cells. It is for people with advanced colorectal or stomach cancer that has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT06791148RecruitingPhase 2
Low-dose radiation plus chemo and immunotherapy for advanced stomach cancer
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Nanjing, JiangsuAges 18–75 - NCT06930755RecruitingPhase 1
Study of an oral drug for recurrent ovarian cancer
This study tests a new oral drug called NMS-03305293 for women with recurrent ovarian cancer. It may work by targeting a specific protein involved in cancer growth. You may be eligible if you have high-grade serous ovarian cancer, have had limited prior treatments, and do not have a BRCA mutation.
Peoria, IllinoisAges 18 years+ - NCT06084299RecruitingPhase 1
Immune cell therapy for advanced liver cancer
This trial tests a new treatment using your own immune cells (tumor-infiltrating lymphocytes) to fight advanced liver cancer. It is for people whose cancer has progressed after at least two standard treatments and who have tumors that can be biopsied to grow these cells.
WuhanAges 18–70 - NCT04107077RecruitingPhase 2
HIPEC surgery plus chemotherapy for advanced stomach cancer
This study tests whether a specialized surgery called HIPEC (heat-treated chemotherapy placed in the belly) can improve outcomes for people with advanced stomach cancer that has reached the lining of the abdomen. It’s given after you’ve already had standard chemotherapy, aiming to better control disease in the belly.
Chicago, IllinoisAges 18 years+ - NCT07754409Recruiting
Quality of life during lung cancer treatment with immunotherapy
This study looks at how patients with advanced lung cancer feel during their treatment, which combines chemotherapy, radiation, and an immunotherapy drug. The goal is to understand and improve quality of life during therapy.
GothenburgAges 18 years+ - NCT07514065RecruitingPhase 1
TSL2109 Safety and Effectiveness Study in Advanced Cancers
This early-stage study tests a new drug called TSL2109 in patients with advanced solid cancers that haven't responded to standard treatment. Researchers want to find the right dose, understand how the body processes it, and see if it can slow or shrink tumors, with special focus on certain prostate and breast cancers.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06193525RecruitingPhase 2
Talazoparib for advanced breast cancer with a DNA repair defect
This trial tests a drug called talazoparib (a PARP inhibitor) for advanced breast cancer that has a specific DNA repair defect (HRD) or a BRCA mutation. The goal is to see if the drug works better when the patient's tumor is tested for this defect just before treatment.
Leiden, South HollandAges 18 years+ - NCT06969612RecruitingPhase 1
New drug combo as first treatment for advanced lung cancer
This trial tests a new combination of three medicines (Golidocitinib, Tislelizumab, and chemotherapy) as the first treatment for advanced non-small cell lung cancer (NSCLC). It is designed for people whose tumors have at least 1% PD-L1 and who have not had any previous treatment for advanced disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07047573Recruiting
Better testing for lung nodules to tell benign from cancer
This study uses advanced testing methods on lung nodules to better tell if they are benign (not cancer) or malignant (cancer). It may help improve diagnosis for people scheduled for surgery to remove a lung nodule.
Suzhou, JiangsuAges Any age - NCT06107374RecruitingPhase 2
New imaging for immunotherapy in advanced lung cancer
This trial tests a special imaging scan called [18F]-FARAG to see how well it shows the activity of immunotherapy in advanced NSCLC. The goal is to help doctors understand if the treatment is working earlier than standard scans.
Iowa City, IowaAges 18 years+ - NCT07596121RecruitingPhase 2
Serplulimab for Advanced Lung Cancer in Older Adults
This trial tests a new immunotherapy drug called serplulimab in patients aged 65 and older with advanced non-small cell lung cancer (NSCLC). The drug works by helping your immune system fight cancer cells that have a specific marker called PD-L1.
Xi'an, ShannxiAges 65 years+ - NCT06667167RecruitingPhase 2
First-line Keytruda + chemo then Keytruda + Trodelvy for SCLC
This trial tests a two-step treatment for extensive-stage small cell lung cancer: first, chemotherapy combined with Keytruda (an immunotherapy), followed by Keytruda plus Trodelvy (another targeted drug). The goal is to see if this combination helps people live longer and keeps the cancer under control.
Jerusalem, IsraelAges 18–99 - NCT06905197RecruitingPhase 1
Study of DZD6008 for advanced NSCLC with EGFR mutations
This trial tests an oral drug called DZD6008 for people with advanced non-small cell lung cancer (NSCLC) that has certain EGFR mutations. It may be an option for those who have tried other EGFR treatments or are new to treatment.
New York, New YorkAges 18 years+ - NCT06813365RecruitingPhase 1
A targeted therapy for EGFR-mutated advanced lung cancer
This trial is testing a new targeted pill for people with EGFR-positive non-small cell lung cancer. It's designed for those whose cancer has grown after other treatments, and it works by blocking a specific protein that helps the cancer grow.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06053099Recruiting
Study of osimertinib after surgery for EGFR-mutated lung cancer
This trial collects data from people with early-stage lung cancer that has a common EGFR mutation. After complete surgical removal of the tumor, participants take osimertinib for 3 years and are followed regularly to see how well the treatment works and why resistance might develop.
AngersAges 18 years+ - NCT06853678Recruiting
Immunotherapy after first treatment for extensive stage small cell lung cancer
This trial tests immunotherapy drugs for extensive stage small cell lung cancer that has progressed after initial (first-line) chemotherapy. You may be eligible if you have finished standard treatment and your cancer has worsened.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06436625Recruiting
Outpatient rehab for lung cancer patients on immunotherapy
This study tests whether a structured outpatient exercise program can help people with non-small cell lung cancer who are already receiving immunotherapy. It is designed for those whose cancer is stable or responding after initial treatment.
ViennaAges 18–120 - NCT06105801RecruitingPhase 4
Comparing two biopsy methods for lung cancer genetic testing
This study compares two ways to get a larger tissue sample from lymph nodes in the chest after a first small test confirmed cancer. The goal is to see which method provides better material for detailed genetic testing (next generation sequencing) that can guide treatment choices.
Nashville, TennesseeAges 18 years+ - NCT06581419RecruitingPhase 1/Phase 2
Testing IAP0971 in advanced solid tumors and lung cancer
This trial tests a new drug called IAP0971 for people with advanced solid tumors or a specific type of lung cancer. It may help if your cancer has not responded to other treatments or if you have PD-L1-positive lung cancer that hasn't been treated yet.
Beijing, Beijing MunicipalityAges 18–75 - NCT07284121Recruiting
Patient satisfaction and safety of Atezolizumab in routine care
This study tracks how well Atezolizumab (Tecentriq) works for people with certain lung or liver cancers in everyday medical practice. It helps doctors understand if patients are satisfied with their treatment and how it affects their quality of life.
KremsAges 18 years+ - NCT07079475RecruitingPhase 1/Phase 2
Study of two targeted pills for EGFR-mutated lung cancer
This trial tests a new combination of two oral targeted drugs for people with advanced non-small cell lung cancer that has an EGFR mutation. It may help if you have already been treated with a third-generation EGFR pill or if you are starting treatment for the first time.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06281964Enrolling by invitationPhase 3
New pill for EGFR Exon 20 lung cancer
This study tests a new pill called PLB1004 for people whose lung cancer has a specific EGFR mutation (exon 20 insertion). It is for those who have not yet had any treatment for their advanced cancer.
Guangzhou, GuangzhouAges 18 years+
Hear when a new Lung Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer patients?
- Yes. Clin2 currently lists 1,877 recruiting lung cancer patients studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer patients trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer patients trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.